Volume | 80,911 |
|
|||||
News | - | ||||||
Day High | 1.429 | Low High |
|||||
Day Low | 1.28 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
InflaRx NV | IFRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.38 | 1.28 | 1.429 | 1.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
486 | 80,911 | $ 1.35 | $ 109,042 | - | 1.14 - 5.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:50:41 | 75 | $ 1.31 | USD |
InflaRx NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
73.6M | 54.12M | - | 63k | -42.67M | -0.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
InflaRx NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.27 | 1.46 | 1.26 | 1.37 | 113,261 | 0.04 | 3.15% |
1 Month | 1.55 | 1.68 | 1.24 | 1.48 | 205,107 | -0.24 | -15.48% |
3 Months | 1.70 | 1.92 | 1.24 | 1.56 | 237,881 | -0.39 | -22.94% |
6 Months | 1.82 | 2.11 | 1.14 | 1.53 | 322,361 | -0.51 | -28.02% |
1 Year | 4.70 | 5.20 | 1.14 | 2.52 | 271,974 | -3.39 | -72.13% |
3 Years | 3.79 | 6.15 | 0.7762 | 3.43 | 546,691 | -2.48 | -65.44% |
5 Years | 49.24 | 50.88 | 0.7762 | 4.09 | 634,549 | -47.93 | -97.34% |
InflaRx NV Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |